These concepts have unveiled a new therapeutic potential for CDK4/6 inhibitors as myeloid-protective agents in retinoblastoma (RB)-deficient cancers, with trilaciclib emerging as the pioneer in this class [7, 8]. Here, CDK4 is linked to cancer.